Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

July 06, 2021

FDA agrees to review additional data to determine adequacy for submission of NDA REDWOOD CITY, ...

Read More

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a

June 02, 2021

REDWOOD CITY, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...

Read More
Soleno – Home